Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-12-19

Clinical Trial Update: Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia [Phase 4]

View source ↗

Summary

Phase 4 trial update on remifentanil IVPCA for ablation of idiopathic ventricular tachycardia; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Remifentanil (remifentanil)

Snippet

Sponsor: NYU Langone Health | Conditions: Tachycardia, Ventricular | Phase 4 | Status: COMPLETED | Results posted: 2014-12-19